Teleconference Call About Advanced Prostate Cancer is Today

A reminder that the Malecare teleconference on advanced prostate cancer is today Conference Time: 6:00 PM ET, 5:00 PM CT, 4:00 PM MT, 3:00PM PT Participant Dialing Instructions: Toll Free Number: 1.800.868.1837 Direct Dial/Int’l Number: 1.404.920.6440 Conference Code: 786432# […]

2010 Statistical Projection of the Death Rate for Prostate Cancer Exceeds the Projection for Breast Cancer

Recent statistics projecting the cancer incidence in the United States for 2010 have a number of interesting items buried inside the data charts. I thought that three items were particularly interesting and relevant, so I want to share them with you. 1- The 2010 expected death rate per 100,000 cases for the "Good Cancer" (prostate [...]

Androgen Deprivation (ADT) and Its Anti-vascular Effects: An in Vivo Human Study

We all know that hormone therapy (ADT2) stops the production of testosterone and blocks the little testosterone that might still be produced from entering into the prostate cancer cell to “feed” the cancer. There have been a number of studies that have investigated and concluded that ADT not only stops testosterone, but also has anti-vascular [...]

Treating Fatigue in Men with Advanced Prostate Cancer

One of the more common experiences many of us have when fighting advanced prostate cancer is fatigue. Despite how common fatigue is in men with advanced disease there has not been even one published controlled trial of interventions for fatigue! A research team at the Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, [...]

Denosumab Demonstrates An Increased Time to First Skeletal Event in Men with Metastatic Prostate Cancer vs Zometa

In men with bone metastasis from castration-resistant prostate cancer (CRPC), a monthly subcutaneous injection with denosumab, 120 mg, is superior to Zometa, a multinational group of researchers reported at the American Society of Clinical Oncology annual meeting. The current standard of care is for men with bone metastasis from castration-resistant prostate cancer (CRPC) is to [...]

Go to Top